Fluorine-18-fluorodeoxyglucose (F-18-FDG) is the most used positron emitter radiopharmaceutical worldwide. This glucose analogue allows to study the glucose metabolism which is often increased in many tumors. Nowadays the diagnostic performance of positron emission tomography/computed tomography (PET/CT) using F-18-FDG in different tumors is well known. On the other hand, to date, there is an increasing interest for the use of PET tracers other than F-18-FDG in oncology, because they allow to study different metabolic pathways or receptor expression. The aim of this review is to summarize the scientific literature about the diagnostic performance of PET/CT using tracers other than F-18-FDG in oncology through an evidence-based approach. In particular, the results of meta-analyses (representing the highest level of evidence) on the diagnostic performance of PET tracers other than F-18-FDG in different tumors are described. Furthermore, recommendations for the use of different PET tracers in oncology are provided based on existing literature data.

Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology : an evidence-based review / G. Treglia, R. Sadeghi, A. Del Sole, L. Giovanella. - In: CLINICAL & TRANSLATIONAL ONCOLOGY. - ISSN 1699-048X. - 16:9(2014 Sep), pp. 770-775. [10.1007/s12094-014-1168-8]

Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology : an evidence-based review

A. Del Sole;
2014

Abstract

Fluorine-18-fluorodeoxyglucose (F-18-FDG) is the most used positron emitter radiopharmaceutical worldwide. This glucose analogue allows to study the glucose metabolism which is often increased in many tumors. Nowadays the diagnostic performance of positron emission tomography/computed tomography (PET/CT) using F-18-FDG in different tumors is well known. On the other hand, to date, there is an increasing interest for the use of PET tracers other than F-18-FDG in oncology, because they allow to study different metabolic pathways or receptor expression. The aim of this review is to summarize the scientific literature about the diagnostic performance of PET/CT using tracers other than F-18-FDG in oncology through an evidence-based approach. In particular, the results of meta-analyses (representing the highest level of evidence) on the diagnostic performance of PET tracers other than F-18-FDG in different tumors are described. Furthermore, recommendations for the use of different PET tracers in oncology are provided based on existing literature data.
Evidence; Meta-analysis; Oncology; PET; PET/CT; Tracer
Settore MED/36 - Diagnostica per Immagini e Radioterapia
Settore MED/06 - Oncologia Medica
set-2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
art%3A10.1007%2Fs12094-014-1168-8.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 210.04 kB
Formato Adobe PDF
210.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/233099
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 24
social impact